Translational insights to de-risk drug development
VitroScan integrates ex vivo micro‑tumor testing into a comprehensive solution that de‑risks drug development and accelerates the translation of new therapies into clinically relevant treatment options.
Therapeutics for micro-tumor testing
Near-clinical testing for impactful decision‑making
VitroScan’s ex vivo platform supports the development and clinical translation of innovative therapeutics through near clinical testing. By preserving tumor heterogeneity and the tumor microenvironment (TME), the platform enables modeling of patient-specific treatment responses. As a new approach methodology (NAM), it delivers insights that capture the real-world patient population. The platform’s predictive value helps to de-risk drug development, inform patient stratification for clinical trials, and helps to prevent late-stage failure of promising new therapies.
- Accelerated development: Efficient drug development through effective selection of relevant indications
- Optimized combination strategies: Identification of optimal (combination) therapies and benchmarking against standard of care
- Validated predictive power: Proven predictive platform for clinical treatment outcomes
- Strategic market access: Generation of reliable data packages to support IND/CTA submissions and market access strategies
By delivering near‑clinical insights, VitroScan empowers partners to make data‑driven decisions that de‑risk pipelines, improve patient selection, and ultimately accelerate the development of effective, life‑changing treatments.
Info Sheets
Download Our latest scientific publication at a glance!
Koedoot et al., npj Precision Oncology, 2025
Download